Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.

Louise M E MüllerMatthew HolmesJoanne L MichaelGina B ScottEmma J WestKaren J ScottChristopher ParrishKathryn HallSina StäbleVictoria A JenningsMatthew CullenStewart McConnellCatherine LangtonEmma L TidswellDarren ShafrenAdel SamsonKevin J HarringtonHardev PandhaChristy RalphRichard J KellyGordon CookAlan A MelcherFiona Errington-Mais

Published in: Journal for immunotherapy of cancer (2019)

This work supports the development of CVA21 as an immunotherapeutic agent for the treatment of both AML and MM. Additionally, the data presented provides an important insight into the mechanisms of CVA21-mediated immunotherapy to aid the development of clinical biomarkers to predict response and rationalize future drug combinations.

Keyphrases

dendritic cells
immune response
regulatory t cells
acute myeloid leukemia
electronic health record
emergency department
big data
machine learning
replacement therapy
drug induced